中国药房2017，Vol.28Issue(4)：462-464,465,4.DOI:10.6039/j.issn.1001-0408.2017.04.08
澳大利亚高值药物医保准入机制简介及对我国罕用药医保准入的启示
Brief Introduction on High-value Drug Insurance Access Mechanism in Australia and Its Enlightenment on Orphan Drug Medical Insurance in China
任昉 1颜建周 1邵蓉1
作者信息
- 1. 中国药科大学国家药物政策与医药产业经济研究中心，南京 211198
- 折叠
摘要
Abstract
OBJECTIVE:To introduce high-value drug insurance access mechanism in Australia,and to provide suggestion for improving orphan drug medical insurance access in China. METHODS:By literature study and policy analysis,access principle, risk-sharing mechanism and restricted use principle of high-value drug insurance access in Australia were summarized and analyzed, so as to evaluate the effects of high-value drug insurance access mechanism. RESULTS & CONCLUSIONS:The inclusion of high-value drug in Australian National Formulary considers not only the cost-effectiveness ratio,but also the drug’s clinical effica-cy,irreplaceability and the social principles;risk-sharing mechanism and restricted use principle achieve a good balance between the accessibility of patient’s medication and the sustainability of health insurance fund;remarkable results are achieved in guarantee-ing patient’s medication and strengthening basic medical insurance. It is recommended to perfect orphan drugs medical insurance ac-cess standard,introduce risk-sharing mechanism and standardize the use of orphan drugs and reimbursement in China.关键词
澳大利亚/高值药物/医保准入机制/罕用药/启示Key words
Australia/High-value drug/Insurance access mechanism/Orphan drug/Enlightenment分类
医药卫生引用本文复制引用
任昉,颜建周,邵蓉..澳大利亚高值药物医保准入机制简介及对我国罕用药医保准入的启示[J].中国药房,2017,28(4):462-464,465,4.
